Product Categories ...
Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.
Hanmi Pharmaceutical Co. Ltd. and Health Hope Pharma Ltd. may be getting a second wind for encequidar and the Orascovery platform, with Gilead Sciences Inc. picking up exclusive global rights to ...
Abera Bioscience AB has announced, together with clinical partner Radboud University Medical Center, the submission of a clinical trial application in the Netherlands to initiate a phase I trial of ...
Researchers from Beacon Therapeutics Holdings Ltd. reported the development of BTX-001, an intravitreal gene therapy designed to target the complement pathway through delivery of a C5 inhibitor. The ...
Medtronic plc is strengthening its pain management portfolio with its $650 million move to buy SPR Therapeutics Inc. and bring the company’s peripheral nerve stimulation system for sustained pain ...
Replicate Bioscience Inc. has been awarded a new grant worth approximately $3 million from the Gates Foundation to accelerate the development of globally accessible tuberculosis (TB) vaccines using ...
CSL Behring’s expensive hemophilia B gene therapy is to be reimbursed by the U.K. National Health Service, after the company agreed to an outcomes-based payment scheme. The therapy, Hemgenix ...
The industry is in support of the EU Biotech Act but says it needs to go further to restore Europe’s competitive position in biopharma. Instead of incremental adjustments, there should be wide-ranging ...
On the heels of a $7 million seed round, Singapore-based medical technology startup Thrixen Pte Ltd. is accelerating development of its diagnostic technology platform that has the potential to perform ...
Chimeric antigen receptor (CAR) T-cell therapy has been a game changer in the treatment of B-cell malignancies, although their manufacturing process is complex and needs lymphodepletion, thus limiting ...
Arnatar Therapeutics Inc. has received clinical trial clearance from China’s National Medical Products Administration (NMPA) for ART-5, a potential first-in-class upregulating antisense ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results